Showing 121 - 140 results of 211 for search '"Hiroshima"', query time: 0.05s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134

    Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study by Mizoguchi Y, Hino M, Ueda H, Miyaguchi Y, Kobayashi M

    Published 2025-01-01
    “…Yoko Mizoguchi,1 Moeko Hino,2 Hitoshi Ueda,3 Yasuo Miyaguchi,3 Masao Kobayashi1,4 1Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; 2Department of Pediatrics, Chiba University Hospital, Chiba, Japan; 3Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 4Japanese Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, JapanCorrespondence: Yasuo Miyaguchi, Japan Medical Office, Takeda Pharmaceutical Company Limited, 2 Chome-1-1 Nihonbashihoncho, Chuo-ku, Tokyo, 103-0023, Japan, Tel +81 70-4921-7966, Email yasuo.miyaguchi1@takeda.comPurpose: Prophylaxis with recombinant factor VIII (rFVIII) products is the gold-standard treatment for hemophilia A. …”
    Get full text
    Article
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140